靶向治疗对多发性鼻炎合并支气管哮喘患者生活质量的影响

A. Korkmazov, M. A. Lengina, M. Korkmazov, N. V. Kornova
{"title":"靶向治疗对多发性鼻炎合并支气管哮喘患者生活质量的影响","authors":"A. Korkmazov, M. A. Lengina, M. Korkmazov, N. V. Kornova","doi":"10.21518/ms2024-208","DOIUrl":null,"url":null,"abstract":"Introduction. The relevance of studying the possibility of using targeted therapy in the treatment of polypous rhinosinusitis in patients with comorbid bronchial asthma is due to the observed growth of the disease and the disclosure of new pathophysiological mechanisms of their development.Aim. Based on the generalization of research results and the analysis of our own clinical observations, to improve the effectiveness of treatment and the quality of life of patients with polypous rhinosinusitis with a history of severe bronchial asthma, using genetically engineered biological therapy.Materials and methods. The literature of the eLibrary databases is analyzed.RU RSCI, Medline, Scopus, Web of Science for the period 2011–2023. The inclusion of monoclonal antibodies in the treatment regimen for diseases that are difficult to treat with medication is based on the results of clinical studies and meta-analysis data. A study of the quality of life was conducted, according to the SF-36 Health Status Survey, 47 patients receiving targeted therapy with monoclonal antibodies in medical and preventive institutions of the megalopolis.Results. The assessment of the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma confirmed the effectiveness of targeted therapy with monoclonal antibodies. According to the SP-36 questionnaire, before treatment, the low-est scores were on the Role-Physical Functioning scales – 51.5 points and General Health – 49.1 points, respectively. At the 2nd and 16th weeks of treatment, gradually increasing positive dynamics was noted on all scales and by the end of the 52nd week of monoclonal antibody use, values as close to normal as possible were recorded in the Social Functioning, Role Emotional, Mental Health scales and amounted to 97.7; 98,3 and 98.7 points. The effectiveness of the treatment was confirmed by two clinical cases.Conclusions. Knowledge of the immunological and pathogenetic mechanisms of the disease allows us to open up significant prospects for diagnosis and treatment. Recommendations and drug selection should be consistently followed within the framework of the clinical recommendations of the relevant diseases. Strict consideration of the development of short-term and long-term risks of the use of genetically engineered biological therapy is necessary.","PeriodicalId":18391,"journal":{"name":"Meditsinskiy sovet = Medical Council","volume":"8 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of targeted therapy on the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma\",\"authors\":\"A. Korkmazov, M. A. Lengina, M. Korkmazov, N. V. Kornova\",\"doi\":\"10.21518/ms2024-208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. The relevance of studying the possibility of using targeted therapy in the treatment of polypous rhinosinusitis in patients with comorbid bronchial asthma is due to the observed growth of the disease and the disclosure of new pathophysiological mechanisms of their development.Aim. Based on the generalization of research results and the analysis of our own clinical observations, to improve the effectiveness of treatment and the quality of life of patients with polypous rhinosinusitis with a history of severe bronchial asthma, using genetically engineered biological therapy.Materials and methods. The literature of the eLibrary databases is analyzed.RU RSCI, Medline, Scopus, Web of Science for the period 2011–2023. The inclusion of monoclonal antibodies in the treatment regimen for diseases that are difficult to treat with medication is based on the results of clinical studies and meta-analysis data. A study of the quality of life was conducted, according to the SF-36 Health Status Survey, 47 patients receiving targeted therapy with monoclonal antibodies in medical and preventive institutions of the megalopolis.Results. The assessment of the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma confirmed the effectiveness of targeted therapy with monoclonal antibodies. According to the SP-36 questionnaire, before treatment, the low-est scores were on the Role-Physical Functioning scales – 51.5 points and General Health – 49.1 points, respectively. At the 2nd and 16th weeks of treatment, gradually increasing positive dynamics was noted on all scales and by the end of the 52nd week of monoclonal antibody use, values as close to normal as possible were recorded in the Social Functioning, Role Emotional, Mental Health scales and amounted to 97.7; 98,3 and 98.7 points. The effectiveness of the treatment was confirmed by two clinical cases.Conclusions. Knowledge of the immunological and pathogenetic mechanisms of the disease allows us to open up significant prospects for diagnosis and treatment. Recommendations and drug selection should be consistently followed within the framework of the clinical recommendations of the relevant diseases. Strict consideration of the development of short-term and long-term risks of the use of genetically engineered biological therapy is necessary.\",\"PeriodicalId\":18391,\"journal\":{\"name\":\"Meditsinskiy sovet = Medical Council\",\"volume\":\"8 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Meditsinskiy sovet = Medical Council\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21518/ms2024-208\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Meditsinskiy sovet = Medical Council","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21518/ms2024-208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言。研究使用靶向疗法治疗合并支气管哮喘的多发性鼻炎患者的可能性具有现实意义,这是因为观察到了该疾病的增长,并揭示了其发展的新病理生理机制。在归纳研究成果和分析自身临床观察结果的基础上,利用基因工程生物疗法提高有严重支气管哮喘病史的多发性鼻炎患者的治疗效果和生活质量。分析了 2011-2023 年期间电子图书馆数据库(RU RSCI、Medline、Scopus、Web of Science)中的文献。根据临床研究结果和荟萃分析数据,将单克隆抗体纳入药物难以治疗的疾病的治疗方案。根据 SF-36 健康状况调查对 47 名在大城市医疗和预防机构接受单克隆抗体靶向治疗的患者进行了生活质量调查。对多发性鼻炎和合并支气管哮喘患者生活质量的评估证实了单克隆抗体靶向治疗的有效性。根据SP-36调查问卷,治疗前,患者在角色-身体功能量表上的得分最低,分别为51.5分和49.1分。在治疗的第 2 周和第 16 周,所有量表的积极动态都在逐渐增加,到使用单克隆抗体的第 52 周结束时,社会功能、角色情感和心理健康量表的数值已尽可能接近正常值,分别达到 97.7 分、98.3 分和 98.7 分。两个临床病例证实了治疗的有效性。对该病免疫学和发病机制的了解为我们的诊断和治疗开辟了广阔的前景。建议和药物选择应始终遵循相关疾病的临床建议框架。有必要严格考虑使用基因工程生物疗法的短期和长期风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The effect of targeted therapy on the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma
Introduction. The relevance of studying the possibility of using targeted therapy in the treatment of polypous rhinosinusitis in patients with comorbid bronchial asthma is due to the observed growth of the disease and the disclosure of new pathophysiological mechanisms of their development.Aim. Based on the generalization of research results and the analysis of our own clinical observations, to improve the effectiveness of treatment and the quality of life of patients with polypous rhinosinusitis with a history of severe bronchial asthma, using genetically engineered biological therapy.Materials and methods. The literature of the eLibrary databases is analyzed.RU RSCI, Medline, Scopus, Web of Science for the period 2011–2023. The inclusion of monoclonal antibodies in the treatment regimen for diseases that are difficult to treat with medication is based on the results of clinical studies and meta-analysis data. A study of the quality of life was conducted, according to the SF-36 Health Status Survey, 47 patients receiving targeted therapy with monoclonal antibodies in medical and preventive institutions of the megalopolis.Results. The assessment of the quality of life of patients with polypous rhinosinusitis and comorbid bronchial asthma confirmed the effectiveness of targeted therapy with monoclonal antibodies. According to the SP-36 questionnaire, before treatment, the low-est scores were on the Role-Physical Functioning scales – 51.5 points and General Health – 49.1 points, respectively. At the 2nd and 16th weeks of treatment, gradually increasing positive dynamics was noted on all scales and by the end of the 52nd week of monoclonal antibody use, values as close to normal as possible were recorded in the Social Functioning, Role Emotional, Mental Health scales and amounted to 97.7; 98,3 and 98.7 points. The effectiveness of the treatment was confirmed by two clinical cases.Conclusions. Knowledge of the immunological and pathogenetic mechanisms of the disease allows us to open up significant prospects for diagnosis and treatment. Recommendations and drug selection should be consistently followed within the framework of the clinical recommendations of the relevant diseases. Strict consideration of the development of short-term and long-term risks of the use of genetically engineered biological therapy is necessary.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical and pathogenetic features of thyropathies diagnosed during the post-COVID-19 period Lung cancer associated with an activating mutation in the 14th exon of the MET gene Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety Experience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1